Ocugen is focused on its product, NeoCart®, a cell therapy that utilizes various aspects of Co.'s restorative cell therapy platform to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee. Co.'s NeoCart Phase 3 clinical trial is designed, randomized clinical trial in North America evaluating the safety and efficacy of a restorative cell therapy to treat knee cartilage damage. Co. has a License and Commercialization Agreement with MEDINET Co., Ltd. with regards to the commercialization of NeoCart in Japan. HISTOGENICS (and design), its logo design and NEOCART are Co.'s registered trademarks. The HSGX average annual return since 2014 is shown above.
The Average Annual Return on the HSGX average annual return since 2014 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether HSGX average annual return since 2014 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the HSGX average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|